Biological Trace Element Research

, Volume 147, Issue 1–3, pp 217–225

Aldehyde and Xanthine Oxidase Activities in Tissues of Streptozotocin-Induced Diabetic Rats: Effects of Vitamin E and Selenium Supplementation

  • Tayyebeh Ghaffari
  • Mohammad Nouri
  • Amir Ata Saei
  • Mohammad-Reza Rashidi


Effects of vitamin E and selenium supplementation on aldehyde oxidase (AO) and xanthine oxidase (XO) activities and antioxidant status in liver, kidney, and heart of streptozotocin (STZ)-induced diabetic rats were examined. AO and XO activities increased significantly after induction of diabetes in rats. Following oral vitamin E (300 mg/kg) and sodium selenite (0.5 mg/kg) intake once a day for 4 weeks, XO activity decreased significantly. AO activity decreased significantly in liver, but remained unchanged in kidney and heart of vitamin E- and selenium-treated rats compared to the diabetic rats. Total antioxidants status, paraoxonase-1 (PON1) and erythrocyte superoxide dismutase activities significantly decreased in the diabetic rats compared to the controls, while a higher fasting plasma glucose level was observed in the diabetic animals. The glutathione peroxidase activity remained statistically unchanged. Malondialdehyde and oxidized low-density lipoprotein levels were higher in the diabetic animals; however, these values were significantly reduced following vitamin E and selenium supplementation. In summary, both AO and XO activities increase in STZ-induced diabetic rats, and vitamin E and selenium supplementation can reduce these activities. The results also indicate that administration of vitamin E and selenium has hypolipidemic, hypoglycemic, and antioxidative effects. It decreases tissue damages in diabetic rats, too.


Streptozotocin-induced diabetes Vitamin E Selenium Aldehyde oxidase Xanthine oxidase Paraxonase 1 


  1. 1.
    King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedGoogle Scholar
  2. 2.
    Strain JJ (1991) Disturbances of micronutrient and antioxidant status in diabetes. Proceedings of the Nutrition Society 50:591–604PubMedGoogle Scholar
  3. 3.
    Ramakrishna V, Jailkhani R (2008) Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 45:41–46PubMedGoogle Scholar
  4. 4.
    Desco MC, Asensi M, Marquez R et al (2002) Xanthine oxidase is involved in free radical production in type 1 diabetes: Protection by allopurinol. Diabetes 51:1118–1124PubMedGoogle Scholar
  5. 5.
    Hunt JV, Dean RT, Wolff SP (1988) Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 256:205–212PubMedGoogle Scholar
  6. 6.
    Jain SK, McVie R, Jaramillo JJ, Chen Y (1998) Hyperketonemia (acetoacetate) increases the oxidizability of LDL + VLDL in Type-I diabetic patients. Free Radic Biol Med 24:175–181PubMedGoogle Scholar
  7. 7.
    Inkster ME, Cotter MA, Cameron NE (2007) Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol 561:63–71PubMedGoogle Scholar
  8. 8.
    Kundu TK, Hille R, Velayutham M, Zweier JL (2007) Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys 460:113–121PubMedGoogle Scholar
  9. 9.
    Higgins P, Ferguson LD, Walters MR (2011) Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach. Expert Rev Cardiovasc Ther 9:399–401PubMedGoogle Scholar
  10. 10.
    Higgins P, Dawson J, Walters M (2009) The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol 2009:282059.Google Scholar
  11. 11.
    Hanachi N, Charef N, Baghiani A et al (2009) Comparison of xanthine oxidase levels in synovial fluid from patients with rheumatoid arthritis and other joint inflammations. Saudi Med J 30:1422–1425PubMedGoogle Scholar
  12. 12.
    Lee BE, Toledo AH, Anaya-Prado R, Roach RR, Toledo-Pereyra LH (2009) Allopurinol, xanthine oxidase, and cardiac ischemia. J Investig Med 57:902–909PubMedGoogle Scholar
  13. 13.
    Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, Utsumi H (2003) Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res 37:767–772PubMedGoogle Scholar
  14. 14.
    Turner NA, Doyle WA, Ventom AM, Bray RC (1995) Properties of rabbit liver aldehyde oxidase and the relationship of the enzyme to xanthine oxidase and dehydrogenase. Eur J Biochem 232:646–657PubMedGoogle Scholar
  15. 15.
    Rashidi MR, Nazemiyeh H (2010) Inhibitory effects of flavonoids on molybdenum hydroxylases activity. Expert Opin Drug Metab Toxicol 6:133–152PubMedGoogle Scholar
  16. 16.
    Gupta S, Sharma TK, Kaushik GG, Shekhawat VP (2011) Vitamin E supplementation may ameliorate oxidative stress in type 1 diabetes mellitus patients. Clin Lab 57:379–386PubMedGoogle Scholar
  17. 17.
    Pazdro R, Burgess JR (2010) The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev 131:276–286PubMedGoogle Scholar
  18. 18.
    Beales PE, Williams AJ, Albertini MC, Pozzilli P (1994) Vitamin E delays diabetes onset in the non-obese diabetic mouse. Horm Metab Res 26:450–452PubMedGoogle Scholar
  19. 19.
    Faure P (2003) Protective effects of antioxidant micronutrients (vitamin E, zinc and selenium) in type 2 diabetes mellitus. Clin Chem Lab Med 41:995–998PubMedGoogle Scholar
  20. 20.
    Ruíz C, Alegría A, Barberá R, Farré R, Lagarda J (1998) Selenium, zinc and copper in plasma of patients with type 1 diabetes mellitus in different metabolic control states. J Trace Elem Med Biol 12:91–95PubMedGoogle Scholar
  21. 21.
    Navarro-Alarcón M, López-G de la Serrana H, Pérez-Valero V, López-Martínez C (1999) Serum and urine selenium concentrations as indicators of body status in patients with diabetes mellitus. Sci Total Environ 228:79–85PubMedGoogle Scholar
  22. 22.
    Marcason W (2008) What is the latest research on the connection between selenium and diabetes? J Am Diet Assoc 108:188PubMedGoogle Scholar
  23. 23.
    Sotiropoulos A, Papadodima SA, Papazafiropoulou AK, Ioannidis A, Kokkinari A, Apostolou O, Spiliopoulou CA, Athanaselis S (2011) Serum selenium levels do not differ in type 2 diabetic subjects with and without coronary artery disease. BMC Res Notes 4:270PubMedGoogle Scholar
  24. 24.
    Bleys J, Navas-Acien A, Guallar E (2007) Serum selenium and diabetes in U.S. adults. Diabetes Care 30:829–834PubMedGoogle Scholar
  25. 25.
    Steinbrenner H, Speckmann B, Pinto A, Sies H (2011) High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr 48:40–45PubMedGoogle Scholar
  26. 26.
    Fernandes AAH, Novelli ELB, Okoshi K et al (2010) Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomedicine and Pharmacotherapy 64:214–219Google Scholar
  27. 27.
    Ramesh B, Pugalendi KV (2006) Antioxidant role of Umbelliferone in STZ-diabetic rats. Life Sciences 79:306–310PubMedGoogle Scholar
  28. 28.
    Pirouzpanah S, Hanaee J, Razavieh SV, Rashidi MR (2009) Inhibitory effects of flavonoids on aldehyde oxidase activity. Enz Inhibit Med Chem 24:14–21Google Scholar
  29. 29.
    Rashidi MR, Amini K, Khani MY, Faridi A, Hanaee J, Sorouraddin MS (2011) A highly sensitive HPLC-florescence method to study aldehyde oxidase activity. JAOAC Int 94:550–554Google Scholar
  30. 30.
    Prajda N, Weber G (1975) Malignant transformation linked imbalance: decreased xanthine oxidase activity in hepatomas. FEBS Letters 59:245–249PubMedGoogle Scholar
  31. 31.
    Burstein M, Scholnick HR, Morfin R (1970) Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11(6):583–595PubMedGoogle Scholar
  32. 32.
    Chait A, Brazg RL, Tribble DL, Krauss RM (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94(4):350–356PubMedGoogle Scholar
  33. 33.
    Drabkin DL (1965) The molecular weight of haemoglobin, its iron and nitrogen content and optical properties—their relevance in the problem of a reference standard for haemoglobin measurement. Bibl Haematol 21:33–42PubMedGoogle Scholar
  34. 34.
    Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158–169PubMedGoogle Scholar
  35. 35.
    Ogura R, Ueta H, Sugiyama M, Hidaka T (1990) Distribution of superoxide dismutase activity in the epidermis: measurement with electron spin resonance spin trapping. J Invest Dermatol 94:227–229PubMedGoogle Scholar
  36. 36.
    Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84(4):407–412Google Scholar
  37. 37.
    Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H, Cloarec L (1993) Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clinica Chimica Acta 214:227–234Google Scholar
  38. 38.
    Jafarnejad A, Bathaie SZ, Nakhjavani M, Hassan MZ (2008) Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model. Life Sciences 82(5–6):301–307PubMedGoogle Scholar
  39. 39.
    Sathishsekar D, Subramanian S (2005) Antioxidant properties of Momordica charantia (bitter gourd) seeds on Streptozotocin induced diabetic rats. Asia Pacific Journal of Clinical Nutrition 14:153–158PubMedGoogle Scholar
  40. 40.
    Johansen JS, Harris AK, Rychly DJ, Ergul A (2005) Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4:5PubMedGoogle Scholar
  41. 41.
    Akirav EM, Chan O, Inouye K, Riddell MC, Matthews SG, Vranic M (2004) Partial leptin restoration increases hypothalamic-pituitary-adrenal activity while diminishing weight loss and hyperphagia in streptozotocin diabetic rats. Metabolism 53:1558–1564PubMedGoogle Scholar
  42. 42.
    Ihara Y, Toyokuni S, Uchida K et al (1999) Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927–932PubMedGoogle Scholar
  43. 43.
    Chen V, Ianuzzo CD (1982) Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 60:1251–1256PubMedGoogle Scholar
  44. 44.
    Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537–546PubMedGoogle Scholar
  45. 45.
    Xue S, Chen X, Lu J, Jin L (2009) Protective effect of sulfated Achyranthes bidentata polysaccharides on streptozotocin-induced oxidative stress in rats. Carbohydrate Polymers 75:415–419Google Scholar
  46. 46.
    Tiedge M, Lortz S, Drinkgern J, Lenzen S (1997) Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733–1742PubMedGoogle Scholar
  47. 47.
    Aliciguzel Y, Ozen I, Aslan M, Karayalcin U (2003) Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142:172–177PubMedGoogle Scholar
  48. 48.
    Dedon PC, Plastaras JP, Rouzer CA, Marnett LJ (1998) Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal. Proc Natl Acad Sci USA 95:11113–11116PubMedGoogle Scholar
  49. 49.
    Garattini E, Fratelli M, Terao M (2008) Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019–1048PubMedGoogle Scholar
  50. 50.
    Krenitsky TA, Spector T, Hall WW (1986) Xanthine oxidase from human liver: purification and characterization. Arch Biochem Biophys 247:108–119PubMedGoogle Scholar
  51. 51.
    Rodrigues AD (1994) Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem Pharmacol 48:197–200PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Tayyebeh Ghaffari
    • 1
    • 2
  • Mohammad Nouri
    • 1
  • Amir Ata Saei
    • 3
  • Mohammad-Reza Rashidi
    • 3
  1. 1.Biochemistry Department, Faculty of MedicineTabriz University of Medical SciencesTabrizIran
  2. 2.Students’ Research CommitteeTabriz University of Medical SciencesTabrizIran
  3. 3.Research Center for Pharmaceutical NanotechnologyTabriz University of Medical SciencesTabrizIran

Personalised recommendations